FDA (Food and Drug Administration). 2004. Innovation Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. [Online]. Available: http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html [accessed October 10, 2005].
FDA. 2005a. Establishment of Prescription Drug User Fee rates for fiscal year 2006. Fed Reg 70(146):44106-44109.
FDA. 2005b. White Paper, Prescription Drug User Fee Act (PDUFA): Adding Resources and Improving Performance in FDA Review of New Drug Applications. [Online]. Available: http://www.fda.gov/oc/pdufa/PDUFAWhitePaper.pdf [accessed December 5, 2005].
Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE, Thompson LJ. 1999. The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA 281(18):1728-1734.
Ganslaw LS. Drug safety: new legal/regulatory approaches. FDLI July/August (4):7-10.
Geraghty LN (The New York Times). 2006. Doctors Fear Acne Drug Rules Go Too Far. [Online]. Available: http://www.nytimes.com/2006/01/12/fashion/thursdaystyles/12skin.html [accessed January 13, 2006].
Gwynne P, Heebner G. 2001. Technologies in drug discovery/drug development: the next generation. Science Aug:1-17.
Hart C. 1999. Drug approvals: safe at any speed? Mod Drug Disc 2(5):25-26, 28.
Herper M. 2005. Five Ways to Fix the FDA. [Online]. Available: http://www.forbes.com/healthcare/2005/01/12/cx_mh_0112fdaintro.html [accessed July 1, 2005].
Joint Commission on Prescription Drug Use. 1980. Report of the Joint Commission on Prescription Drug Use. KF3869.R4. Rockville, MD.
Kaiser Family Foundation. 2005. Kaiser HealthPoll Report Views on Prescription Drugs and the Pharmaceutical Industry. [Online]. Available: http://www.kff.org/healthpollreport/feb_2005/upload/full_report.pdf [accessed September 22, 2005].
Kleinke JD, Gottlieb S. 1998. Is the FDA approving drugs too fast? Probably not—but drug recalls have sparked debate. [see comment]. BMJ 317(7163):899.
Landow L. 1999. FDA approves drugs even when experts on its advisory panels raise safety questions. BMJ 318(7188):944.
Lurie P, Wolfe SM. 1998. FDA Medical Officers Report Lowers Standards Permit Dangerous Drug Approvals. [Online]. Available: http://www.citizen.org/publications/release.cfm?ID=7104 [accessed October 15, 2005].
Lurie P, Sasich LD. 1999. Safety of FDA-approved drugs. JAMA 282(24):2297-2298.
Markel H. 2005. Why America needs a strong FDA. JAMA 294(19):2489-2491.
Moses H, Dorsey ER, Matheson DHM, Their SO. 2005. Financial anatomy of biomedical research. JAMA 294(11):1333-1342.
PricewaterhouseCoopers’ Health Research Institute. 2005. Recapturing the Vision:Integrity Driven Performance in the Pharmaceutical Industry. [Online]. Available: http://www.pwc.com/extweb/pwcpublications.nsf/docid/EE74BACB6DE454768525702A00630CFF [accessed March 10, 2006].
Stergachis A, Hazlet T. 2002. Pharmacoepidemiology. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiologic Approach. New York: McGraw-Hill Medical. Pp. 91-97.
Swann JP. 1998. History of the FDA. [Online]. Available: http://www.fda.gov/oc/history/historyoffda/fulltext.html [accessed January 14, 2006].
Tatsioni A, Gerasi E, Charitidou E, Simou N, Mavreas V, Ioannidis JP. 2003. Important drug safety information on the internet: assessing its accuracy and reliability. Drug Saf 26(7):519-527.
Tauzin B. 2002. Reauthorization of the Prescription Drug User Fee Act. Statement at the March 6, 2002 Hearing of the Committee on Energy and Commerce. [Online]. Available: http://energycommerce.house.gov/107/action/107-93.pdf [accessed September 14, 2006].